eMedicine Specialties > Hematology > Immune System and Disorders

Splenomegaly: Differential Diagnoses & Workup

Author: David J Draper, MD, Hematology/Oncology Fellow, The University Hospital, Cincinnati, Ohio
Coauthor(s): Ronald A Sacher, MB, BCh, MD, FRCPC, Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center; Emmanuel N Dessypris, MD, Professor of Medicine, Medical College of Virginia; Chief, Medical Service, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Lewis J Kaplan, MD, FACS, FCCM, FCCP, Director, SICU and Surgical Critical Care Fellowship, Associate Professor, Department of Surgery, Section of Trauma, Surgical Critical Care, and Surgical Emergencies, Yale University School of Medicine
Contributor Information and Disclosures

Updated: Oct 4, 2009

Differential Diagnoses

Berylliosis
Portal Vein Obstruction
Budd-Chiari Syndrome
Schistosomiasis
Cirrhosis
Sepsis, Bacterial
Hepatitis, Viral
Sickle Cell Anemia
Histoplasmosis
Spherocytosis, Hereditary
Hodgkin Disease
Splenic Abscess
Immune Thrombocytopenic Purpura
Systemic Lupus Erythematosus
Infectious Mononucleosis
Thalassemia, Alpha
Infective Endocarditis
Thalassemia, Beta
Iron Deficiency Anemia
Tuberculosis
Leishmaniasis
Malaria
Myeloproliferative Disease

Other Problems to Be Considered

Angioimmunoblastic lymphadenopathy
Banti disease
Congestive heart failure
Drug reactions with serum sickness syndromes
Gaucher disease
Histiocytosis X
Hyperlipidemias
Idiopathic splenomegaly
Immune hemolytic anemias
Leukocyte disorders
Lymphomas
Mucopolysaccharidosis
Niemann-Pick disease
Ovalocytosis
Splenic vein obstruction
Symptomatic human immunodeficiency virus (HIV) infection
Trypanosomiasis

Workup

Laboratory Studies

  • Perform a complete blood cell (CBC) count with differential, platelet count, and peripheral blood smear in cases of splenomegaly.
  • The term hypersplenism describes some of the sequelae that are often observed with splenomegaly. Criteria for a diagnosis of hypersplenism include anemia, leukopenia, thrombocytopenia, or combinations thereof, plus cellular bone marrow, splenomegaly, and improvement after splenectomy.
    • Anemia: The etiology of the anemia observed in splenomegaly is the result of sequestration and hemodilution.
    • Leukopenia: Increased destruction or sequestration of leukocytes causes the leukopenia observed in splenomegaly. Leukopenia is closely related to neutropenia. Neutropenia (absolute neutrophil count [ANC] <2000 × 106/L) is the result of an increase in the marginated granulocyte pool, a portion of which is located in the spleen. Sequestration may also play a role in the genesis of neutropenia.
    • Thrombocytopenia: Approximately 30% of the total platelet mass exists as an exchangeable pool in the spleen. Increased splenic platelet pooling is the primary cause of the thrombocytopenia of hypersplenism. In patients with hypersplenism, as much as 90% of the total platelet mass can be found in the spleen. In hypersplenism, the platelet count is usually 50,000-150,000/µL.

Imaging Studies

  • Craniocaudal measurement: A craniocaudal measurement of 11-13 cm is frequently used as the upper limit of normal for splenic size in imaging studies. However, because of wide variations in shape, no consistent correlation has been recognized between the spleen's length and its overall volume, as has been determined for other organs (eg, kidney).
  • Computed tomography (CT) scanning4
    • The underlying histologic anatomy of the spleen largely determines its characteristic appearance on abdominal CT scan images. On unenhanced CT scan images, the spleen has an attenuation similar to that of the liver, approximately 40 henry (H). Normally, the liver and spleen densities are within 25 H on dynamic contrast-enhanced CT scan images.
    • In general, the spleen can be considered enlarged if its craniocaudal length is > 10 cm on conventional CT scans. A spleen that extends below the lower third pole of the kidney is also indicative of splenomegaly.
    • A CT scan remains the most useful preoperative investigation to measure splenic volume; to exclude lymph nodes at the splenic hilum; and to detect accessory spleens, splenic abscesses, and perisplenitis.
    • Findings that indicate radiologic distinction between benign and malignant lesions are inconsistent and cannot be relied upon to establish or refute a diagnosis of malignancy.
    • CT scanning is the imaging study of choice for identification of inflammatory changes.
    • CT scanning is sensitive for detecting mass lesions, calcifications, infarcts, and cysts.
  • Splenoportography
    • This modality is used to evaluate portal vein patency and the distribution of collateral vessels before shunt operations for cirrhosis.
    • Findings can help identify the cause of idiopathic splenomegaly, especially in children.
  • Angiography: Angiographic findings are used to differentiate splenic cysts from other splenic tumors.
  • Liver-spleen colloid scanning
    • Erythrocytes are labeled with chromium-51 (51 Cr) , mercury-197 (197 Hg), rubidium-81 (81 Rb), or technetium-99m (99m Tc), and the cells are altered by treatment with heat, antibody, chemicals, or metal ions so that the spleen sequesters them after infusion.
    • A spleen length >14 cm is consider enlarged on liver-spleen scan
    • A spleen scan is a good noninvasive technique for evaluating spleen size; a close correlation exists between spleen length on the scan images and spleen weight after splenectomy.
    • A spleen scan is useful for detecting space-occupying lesions in the splenic substance, evaluating loss of spleen functions, assessing for the absence of a spleen, or determining the presence of an accessory spleen.
  • Ultrasonography: This is a noninvasive, highly sensitive, and specific imaging technique for the evaluation of spleen size.

Procedures

History and physical examination, laboratory studies, and CT scanning can help clinicians determine the etiology of splenomegaly in greater than 90% of cases. Occasionally, it is necessary to obtain splenic tissue for pathologic evaluation.

  • Splenectomy
    • Splenectomy may be considered in certain individuals to determine the etiology of splenomegaly.5,6,7,8,9 The need for a diagnosis must be carefully weighed against the confounding morbidity associated with the asplenic state. Splenectomy is typically performed laparoscopically; even supramassive spleens can be removed by laparoscopic surgery with minimal morbidity.9,10
    • Splenectomy is therapeutic in individuals with severe pancytopenia due to splenomegaly.
  • Splenic biopsy
    • Splenic biopsy may be performed in specialized institutions. Severe bleeding is a frequent complication that limits the usefulness of this procedure.

Histologic Findings

When referring to an enlarged spleen as hypertrophied, the underlying cause may be hypertrophy or hyperplasia of individual cells. In specific diseases, the splenic architecture is remodeled. For example, in Niemann-Pick disease, sphingomyelin and cholesterol accumulate within large foamy cells, which is characteristic of this disease. With amyloidosis involving the spleen and resulting in splenomegaly, large hyaline masses are seen as lesions occupying the white pulp space. Two forms exist, including the "sago spleen," in which amyloid deposits are limited to follicles, and the "lardaceous spleen," in which amyloid is deposited in the walls of the splenic sinusoids. In a rare complication of typhoid fever, reactive splenic vasculitis may develop.

More on Splenomegaly

Overview: Splenomegaly
Differential Diagnoses & Workup: Splenomegaly
Treatment & Medication: Splenomegaly
Follow-up: Splenomegaly
Multimedia: Splenomegaly
References
Further Reading

References

  1. Eichner ER. Splenic function: normal, too much and too little. Am J Med. Feb 1979;66(2):311-20. [Medline].

  2. Zhu JH, Wang YD, Ye ZY, Zhao T, Zhu YW, Xie ZJ, et al. Laparoscopic versus open splenectomy for hypersplenism secondary to liver cirrhosis. Surg Laparosc Endosc Percutan Tech. Jun 2009;19(3):258-62. [Medline].

  3. Anegawa G, Kawanaka H, Uehara H, Akahoshi T, Konishi K, Yoshida D, et al. Effect of laparoscopic splenectomy on portal hypertensive gastropathy in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol. Sep 2009;24(9):1554-8. [Medline].

  4. Bezerra AS, D'Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement?. AJR Am J Roentgenol. May 2005;184(5):1510-3. [Medline][Full Text].

  5. Goldstone J. Splenectomy for massive splenomegaly. Am J Surg. Mar 1978;135(3):385-8. [Medline].

  6. Laws HL, Burlingame MW, Carpenter JT, Prchal JT, Conrad ME. Splenectomy for hematologic disease. Surg Gynecol Obstet. Oct 1979;149(4):509-12. [Medline].

  7. Musser G, Lazar G, Hocking W, Busuttil RW. Splenectomy for hematologic disease. The UCLA experience with 306 patients. Ann Surg. Jul 1984;200(1):40-5. [Medline][Full Text].

  8. Wilhelm MC, Jones RE, McGehee R, et al. Splenectomy in hematologic disorders. The ever-changing indications. Ann Surg. May 1988;207(5):581-9. [Medline][Full Text].

  9. Flowers JL, Lefor AT, Steers J, et al. Laparoscopic splenectomy in patients with hematologic diseases. Ann Surg. Jul 1996;224(1):19-28. [Medline][Full Text].

  10. Wang KX, Hu SY, Zhang GY, Chen B, Zhang HF. Hand-assisted laparoscopic splenectomy for splenomegaly: a comparative study with conventional laparoscopic splenectomy. Chin Med J (Engl). Jan 5 2007;120(1):41-5. [Medline][Full Text].

  11. Subhasis RC, Rajiv C, Kumar SA, Kumar AV, Kumar PA. Surgical treatment of massive splenomegaly and severe hypersplenism secondary to extrahepatic portal venous obstruction in children. Surg Today. 2007;37(1):19-23. [Medline].

  12. Kawanaka H, Akahoshi T, Kinjo N, Konishi K, Yoshida D, Anegawa G, et al. Technical standardization of laparoscopic splenectomy harmonized with hand-assisted laparoscopic surgery for patients with liver cirrhosis and hypersplenism. J Hepatobiliary Pancreat Surg. Jul 22 2009;[Medline].

  13. Xu WL, Li SL, Wang Y, Shi BJ, Li M, Li YC, et al. Laparoscopic splenectomy: color Doppler flow imaging for preoperative evaluation. Chin Med J (Engl). May 20 2009;122(10):1203-8. [Medline].

  14. Shaw JH, Print CG. Postsplenectomy sepsis. Br J Surg. Oct 1989;76(10):1074-81. [Medline].

  15. Poulin EC, Mamazza J, Schlachta CM. Splenic artery embolization before laparoscopic splenectomy. An update. Surg Endosc. Jun 1998;12(6):870-5. [Medline].

Further Reading

Related eMedicine Topics

Clinical Trial
Clinical Guidelines

Keywords

splenomegaly, enlarged spleen, splenectomy, ruptured spleen, hypersplenism, spleen enlargement, splenic enlargement, enlargement of the spleen, subacute bacterial endocarditis, SBE, infectious mononucleosis, hereditary spherocytosis, thalassemia major, splenic vein thrombosis, portal hypertension, chronic myeloid metaplasia, sarcoidosis, neoplasm, chronic lymphocytic leukemia, CLL, lymphoma,trauma, cyst, hemangioma, metastasis, giant abscess, tropical splenomegaly syndrome, hyperactive malarial syndrome, splenic injury 

Contributor Information and Disclosures

Author

David J Draper, MD, Hematology/Oncology Fellow, The University Hospital, Cincinnati, Ohio
Disclosure: Nothing to disclose.

Coauthor(s)

Ronald A Sacher, MB, BCh, MD, FRCPC, Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center
Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Society of Hematology
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Emmanuel N Dessypris, MD, Professor of Medicine, Medical College of Virginia; Chief, Medical Service, Hunter Holmes McGuire Department of Veterans Affairs Medical Center
Emmanuel N Dessypris, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society of Hematology, New York Academy of Sciences, Society for Experimental Biology and Medicine, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

Lewis J Kaplan, MD, FACS, FCCM, FCCP, Director, SICU and Surgical Critical Care Fellowship, Associate Professor, Department of Surgery, Section of Trauma, Surgical Critical Care, and Surgical Emergencies, Yale University School of Medicine
Lewis J Kaplan, MD, FACS, FCCM, FCCP is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Surgeons, Association for Academic Surgery, Association for Surgical Education, Connecticut State Medical Society, Eastern Association for the Surgery of Trauma, International Trauma Anesthesia and Critical Care Society, Society for the Advancement of Blood Management, Society of Critical Care Medicine, and Surgical Infection Society
Disclosure: Nothing to disclose.

Medical Editor

Wadie F Bahou, MD, Chief, Division of Hematology, Hematology/Oncology Fellowship Director, Professor, Department of Internal Medicine, State University of New York at Stony Brook
Wadie F Bahou, MD is a member of the following medical societies: American Society of Hematology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Marcel E Conrad, MD, (Retired) Distinguished Professor of Medicine, University of South Alabama
Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, and Southwest Oncology Group
Disclosure: No financial interests None None

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.